INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

BACKGROUND: Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Veyssière, Hugo, Lusho, Sejdi, Molnar, Ioana, Kossai, Myriam, Bernadach, Maureen, Abrial, Catherine, Bidet, Yannick, Radosevic-Robin, Nina, Durando, Xavier
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8268015/
https://ncbi.nlm.nih.gov/pubmed/34249690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.653370
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky